We are excited to announce an $800,000 donation to Mount Sinai to support a clinical trial of the drug rapamycin in patients with long COVID. The trial will be conducted at CoRE: a clinic directed by Dr. David Putrino and PolyBio's Dr. Amy Proal:
polybio.org/polybio-suppor… 2/ "We extremely motivated to run a clinical trial for an affordable, generic drug with the potential to help long COVID patients" says Dr. Proal, who serves as PolyBio's President and Scientific Director of CoRE.

PolyBio’s Fall Symposium is fast approaching on Friday November 8!

From 11 AM to 5 PM, our partner scientists will discuss updates to their #longcovid research projects. The lightning talk schedule is as follows:

polybio.org/fall-2024-symp… Amy Proal, PhD
PolyBio Research Foundation
11:00 – 11:10 am ET (3:00- 3:10 pm UTC)
An overview of PolyBio’s complex chronic illness research & clinical trials program

PolyBio Research Foundation is excited to announce a $1M donation to UCSF.  The donation will allow the UCSF LIINC team to study #ME/CFS patients with advanced technologies, several of which have never yet been used in the field: polybio.org/1m-polybio-don…
2/ Funds for the collaboration were gifted to PolyBio from several #ME/CFS families and Kanro – a philanthropic fund to support open source #scientific research established by Vitalik Buterin, creator of Ethereum.

Yes enough already! These leads on #LongCovid disease mechanisms are HUGE, which is why we’re doing everything in our power to support the team moving forward

https://twitter.com/cjmaddison/status/1820197882101702657

2/ First we’re supporting the LIINC study, in part to serve as as a clinical sample & data core for the #LongCovid Research Consortium (LCRC), with samples shared with other international teams: polybio.org/projects/suppo…

We are excited to have supported this new study via our #LongCovid Research Consortium.  The project team are our incredible @CUBoulderBN colleagues at the University of Colorado Boulder: polybio.org/multiple-hit-m…
2/ The findings suggest that multiple infectious “hits” (#viral and #bacterial) may amplify long-term neuroinflammatory or neuroimmune symptoms in patients with #LongCovid.

Breaking!: Research published today in Science Translational Medicine and supported by PolyBio Research Foundation shows that the #SARS-CoV-2 virus can chronically persist in the gut of patients with long COVID for over 2 years: polybio.org/chronic-virus-… 2/ The findings, published by a UCSF team known for innovation in HIV research, also documented T cell immune activation across the bodies and brains of people after COVID. This T cell activation was particularly elevated in the spinal cord and gut wall of long COVID participants

The PolyBio Symposium is just a week away!

Scientists from our #LongCovid Research Consortium will give 10 min lightning talks on their research/clinical trial projects: polybio.org/spring-2024-sy… 2/ Talks will share new developments on #SARS-CoV-2 persistence, the impact of infection on #neurodegenerative & cardiovascular disease, new treatment pathways, and more.

They include:

We are proud to have supported this new paper published in @BrainBehavImm.

Led by @MBVanElzakker & team at @MGHMartinos, it is the is first study to document neuroinflammation in the long COVID brain along with evidence of vascular problems: polybio.org/longcovid-brai… 2/ Neuroinflammation was located in some #brain areas that are exposed to circulating blood factors via gaps in the “blood-brain barrier” of the brain’s blood vessels.

Great to see this new piece in @ScienceMagazine highlighting LongCovid clinical trials working to target #SARS-CoV-2 persistence. We are proud to be supporting nearly all the teams/trials mentioned in the piece via our LongCovid Research Consortium: science.org/content/articl… 2/ They include the trial at Sinai where @PutrinoLab , @polybio’s Dr. Amy Proal and Akiko Iwasaki’s group at Yale “will study two broad-spectrum antivirals that don’t require viral replication to work: Truvada and Selzentry, both approved for HIV”: polybio.org/projects/a-cli…

We are excited to announce a 2nd series of collaborative projects & clinical trials supported via our LongCovid Research Consortium: polybio.org/new-longcovid-… 2/ The projects/trials further address #SARS-CoV-2 persistence in #LongCOVID, plus the impact of viral activity on #Alzheimer’s & cardiovascular disease. They include:

PolyBio is glad to have supported this Nature Immunology paper showing #LongCovid immune dysregulation connected to potential #SARS-CoV-2 tissue reservoirs. Learn more about the findings here: polybio.org/polybio-suppor… 2/ Overall, Long COVID patients showed differences in the distributions of their T cells, implying ongoing #immune responses. The team also documented a mis-coordination between the SARS-CoV-2-specific T and B cell responses of Long COVID patients.

We are excited to announce a $15M gift from Kanro: a philanthropic fund to support scientific research established by Vitalik Buterin, co-founder of Ethereum: finance.yahoo.com/news/polybio-r… 2/ The funding will support a second phase of research and clinical trials via the #LongCovid Research Consortium (LCRC): a global scientific collaboration to rapidly and openly study core biological drivers of Long COVID: polybio.org/longcovid

We are excited to share that @MBVanElzakker & team at @MGHMartinos have published a preprint with the results of a high-resolution #LongCovid imaging study. They identified neuroinflammation across a wide range of brain regions in LongCovid patients: polybio.org/polybio-suppor… 2/ They additionally found that #neuroinflammation positively correlated with blood measures related to vascular dysfunction. The study is supported via our LongCovid Research Consortium

PolyBio is proud to have supported this new study by @MichaelPelusoMD & team. They identified tissue-based T cell activation in body sites such as brainstem/bone marrow + #SARS-CoV-2 RNA persistence in colorectal tissue up to 2 years post-COVID-19: medrxiv.org/content/10.110… 2/ More specifically they performed whole-body positron emission tomography (#PET) imaging in a group of 24 participants at time points ranging from 27-910 days following acute SARS-CoV-2 infection using a novel radiotracer that quantifies activated T lymphocytes

PolyBio is excited to be leading the LongCovid Research Consortium (LCRC): a global scientific collaboration to rapidly & comprehensively study #LongCovid disease mechanisms, with a focus on SARS-CoV-2 reservoir (). LCRC projects we are supporting include:polybio.org/longcovid 1. Perelman School of Medicine University of Pennsylvania: “Long COVID: Using #SARS-CoV-2 specific T cells as biosensors of viral persistence” 👉 Learn more here: polybio.org/projects/long-…

This is an important talk @resiapretorius gave at the @polybioRF Seminar Series. Her early pilot data (~10 subjects) shows that #LongCovid patients have abnormal microclots in their blood samples that are indicative of endothelial + platelet dysfunction: 2/ The microclots in the LongCovid samples contain serum amyloid A, fibrinogen, complement factors, and cytoskeletal kerratin. Dr. Pretorius has already filed a patent for diagnosing #LongCovid using detection of these deposits. She is also writing a paper on her findings.